Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb and AstraZeneca have confirmed approval by the European Commission for Onglyza (saxagliptin), used as a combination therapy with insulin to improve blood sugar (glycaemic) control in individuals with type 2 diabetes.
Subscribe to our email newsletter
The approval is backed by Phase 3b 24-week data that demonstrated the efficacy of Onglyza in reducing blood sugar levels in type 2 diabetes as compared to placebo.
AstraZeneca chief medical officer Howard Hutchinson said the move by the European agency would help in the development of type 2 diabetes treatment.
Bristol-Myers Squibb and AstraZeneca entered into a research collaboration in January 2007 for the development of select investigational drugs for type 2 diabetes.
Onglyza is a trademark of the Bristol-Myers Squibb Company.